Leon Fogelfeld, MD
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1699732305
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $52 of the $64 with a category attached, or 80.8%. 4 manufacturers reported payments, led by Dexcom, Inc. at 29.6% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in IL, where the typical reported total is $721.
Across 4 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$19
- Tandem Diabetes Care, Inc.$18
- Corcept Therapeutics$15
- Xeris Pharmaceuticals, Inc.$12
Across 745 payments — averaging $1968.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$572K
- Eli Lilly$392K
- Bayer$364K
- Sanofi-aventis U.S. LLC$66K
- Lexicon Pharmaceuticals, Inc.$51K
- Gilead$15K
- plus $6K from 1 others
What the payments were for
- Food & beverage$5281%
- Education$1219%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$64 in reported general payments places this provider in the 10th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $57,922 |
| JardianceEmpagliflozin | 39 | $51,628 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $26,197 |
| ProliaDenosumab | 14 | $23,170 |
| JanuviaSitagliptin Phosphate | 22 | $21,516 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $20,605 |
| MounjaroTirzepatide | 14 | $14,113 |
| TradjentaLinagliptin | 15 | $11,196 |
| EliquisApixaban | 12 | $6,675 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $5,455 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $4,898 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $4,847 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 46 | $3,988 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,743 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $1,703 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.